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Background: Methotrexate is a commonly used anti-inflammatory and immunosuppressive drug. There is growing
evidence that inflammatory processes are involved in the pathogenesis of schizophrenia. In our recent randomised
double-blind placebo-controlled clinical trial in Pakistan and Brazil, the addition of minocycline (antibiotic and
anti-inflammatory drug) for 1 year to treatment as usual reduced negative symptoms and improved some cognitive
measures. A meta-analysis of cytokine changes in the peripheral blood has identified IL-2, IFN-gamma, TNF-alpha
and soluble IL-2 receptor as trait markers of schizophrenia because their levels were elevated during acute exacerbations
and reduced in remission. This suggests immune activation and an inflammatory syndrome in schizophrenia. Based on
the evidence of the strong anti-inflammatory properties of methotrexate, we propose that low-dose methotrexate may
be an effective therapy in early schizophrenia.
Methods/Design: This is a double-blind placebo-controlled study of methotrexate added to treatment as usual for
patients suffering from schizophrenia, schizoaffective disorder, psychosis not otherwise specified or schizophreniform
disorder. This will be with 72 patients, 36 in each arm over 3 months. There will be screening, randomisation and
follow-up visits. Full clinical assessments will be carried out at baseline, 2, 4, 8 and 12 weeks. Social and cognitive
assessments will be carried out at baseline and 12 weeks. Methotrexate will be given at a dose of 10 mgs orally once a
week for a 3-month period.
Discussion: Evidence suggests inflammatory processes are involved in the pathogenesis of schizophrenia and
anti-inflammatory treatments have shown to have some beneficial effects. Methotrexate is a known immunosuppressant
and anti-inflammatory drug. The aim of this study is to establish the degree of improvement in positive and negative
symptoms, as well as cognitive functioning with the addition of methotrexate to treatment as usual.
ClinicalTrials.gov identifier: NCT02074319 (24 February 2014).Background
Methotrexate (MXTis a commonly used anti-inflammatory
and immunosuppressive drug, originally developed and
continuing to be used for chemotherapy either alone or in
combination with other agents. It is used as a treatment
for some autoimmune diseases, including arthritis,* Correspondence: ibchaudhry@btinternet.com
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Low-dose MXT has been used for treatment of rheuma-
toid arthritis for almost 50 years, is very effective and is
recognised as treatment of choice and first-line therapy
for many patients [1]. MXT is thought to affect cancer
and rheumatoid arthritis by two different pathways. For
cancer, MXT competitively inhibits dihydrofolate reduc-
tase (DHFR), an enzyme that participates in the tetrahy-
drofolate synthesis [2]. However, in rheumatoid arthritis itral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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purine metabolism or by inhibition of T cell activation [3].
There has been interest in using MXT in other con-
ditions where excessive immune activation and inflam-
matory mediators are believed to be involved in the
pathogenesis. For example, Gong et al. [4] showed that
in cardiac failure patients, low-dose MXT has significant
anti-inflammatory effects and improved functional out-
comes and quality of life. In an animal model of cardiac
failure Zhang et al. [5] showed that MXT has the ability
to regulate inflammatory responses and improve cardiac
function, hence contributing to prevent the development
of post-myocarditis dilated cardiomyopathy.
There is growing evidence that inflammatory processes
are involved in the pathogenesis of schizophrenia [6]. In
our recent randomised double-blind placebo-controlled
clinical trial in Pakistan and Brazil, funded by the Stanley
Medical Research Institute (SMRI), the addition of min-
ocycline (an antibiotic and anti-inflammatory drug) for
1 year to treatment as usual (TAU) reduced negative
symptoms and improved some cognitive measures [7].
Several studies have noted increase in peripheral inflam-
matory cytokines, such as IL-1, IL-2, IL-6, and TNF-alpha
[8]. In the brain, cytokines seem to be involved in regu-
lating the action of several neurotransmitters, such as
serotonin, noradrenalin, dopamine, and glutamate. The
interaction of cytokines with dopamine and glutamate
seems to be especially relevant to the pathophysiology of
schizophrenia [9].
A meta-analysis of cytokine changes in the peripheral
blood has identified IL-12, IFN-gamma, TNF-alpha, and
soluble IL-2 receptor (sIL-2R) as trait markers of schizo-
phrenia because their levels were elevated during acute
exacerbations and remission [10]. An extensive meta-
analysis by Potvin et al. [8] reports significant increases
in in vivo peripheral levels of IL-1RA, sIL-2R, and IL-6
in schizophrenia patients, supporting evidence of immune
activation and an inflammatory syndrome in schizophre-
nia. Studies show that IL-6 mediates the deleterious effects
of noncompeting N-methyl-D-aspartate (NMDA) antago-
nists on cortical interneurons [11] and cytokines have an
impact on the regulation of neuroplasticity, cellular re-
silience, and apoptosis control [12]. TNF-alpha seems to
inhibit brain-derived neurotrophic factor (BDNF) release,
compromising the protective effect of this neurotrophin.
A number of studies report that treatment with anti-
psychotic drugs affects the cytokine network [13]. This
supports the rationale that the influence of antipsychotics
on the cytokine systems may be responsible for their
clinical efficacy in schizophrenia. Peripheral immune
processes may be mirrored in the brain by microglial
cells [6]. The 'microglia hypothesis of schizophrenia'
suggests that the release of proinflammatory cytokines,
kynurenines, nitric oxide (NO) and reactive oxygen species(ROS) by activated microglia might cause neuronal
degeneration, white matter abnormalities and decreased
neurogenesis [14-16]. Recent positron emission tom-
ography (PET) studies during acute psychotic episodes
in early schizophrenia suggest an activation of micro-
glia [17,18].
If MXT, which is already on the market for the treat-
ment of heart disease, cancer and rheumatic diseases,
proves effective for reducing symptoms of schizophrenia
then this could transform the suffering evidenced by
patients which severely impairs their quality of life.
Targeting the inflammatory response is a major focus
of novel drug development especially relevant to the treat-
ment of Treatment Resistant Schizophrenia (TRS). Based
on the evidence of strong anti-inflammatory properties of
MXT, we propose that low-dose MXT may be an effective
therapy in early schizophrenia.
AIMS
To test the prediction that addition of MXT to treatment
as usual (TAU) for patients with early schizophrenia will
result in following outcomes:
○ To demonstrate that the trial design is acceptable to
participants including randomisation to x arms
○ To demonstrate that the interventions are acceptable
to participants and indicate likely attrition rates and
tolerabilityImprovement in negative symptoms
○ Improvement in positive symptoms
○ Improvement in social functioning
○ Improvement in cognitive functions
Methods/Design
Overview
This is a double-blind placebo-controlled trial of MXT
added to TAU for patients suffering from schizophrenia,
schizoaffective disorder, psychosis not otherwise speci-
fied or schizophreniform disorder. The ethical approval
covering all sites was obtained from the Research and
Ethics Committee of the Pakistan Institute of Learning
and Living and was submitted to the funding body,
SMRI (Project Reference: PILL/SMRI/12627). Patients
will be recruited from inpatient and outpatient settings.
They will initially be approached by the treating psychia-
trists and the multi-disciplinary teams (MDT). Patients
will continue to take TAU during the trial. Although, the
study assessments will be carried out by the research
assistants (RAs), the responsible clinician (consultant
psychiatrist) will remain in charge of the overall treat-
ment. Antipsychotic dosage will be kept constant, unless
clinically warranted, any changes will be recorded on
monthly reviews.
After consenting to take part in the study, 72 patients
will be randomised into two groups: 36 in each arm over
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ried out at baseline, 2, 4, 8 and 12 weeks. Social and cog-
nitive assessments will be carried out at baseline and
12 weeks (Table 1). MXT once a week or placebo once a
week will be added to TAU. Tolerability will be assessed
by self report. During the course of the study the patient
will also have additional support by doctors and RAs
from the research team and continued support from
their mental health care team. If necessary, members of
the research team will be available 24 hours a day, 7 days
a week.
Allocation
In this study patients will be allocated to treatment
group according to a randomised permuted blocks algo-
rithm, after stratification by centre. Allocation will be
determined in Manchester by pseudo-random numberTable 1 Schedule of assessments
Assessment Who
Patient Research assistants RMO team
Case note review x
SCID x
Drug treatment history x
Medical history x
Physical exam x
Body weight and BMI x
BP and HR x
Lab screena x















methotrexate toxicity check list x x
Compliance monitoring x
aLab screen includes FBC, renal function and liver functions tests. Patients will conti
6-week blood tests that do not warrant withdrawal from the study. These blood tes
are conducted at baseline and 12 weeks.
Abbreviations: BMI body mass index, BP blood pressure, CGI Clinical Global Impressio
PANNS Positive and Negative Syndrome Scale, QOL quality of life, RMO resident megeneration by the trial statistician. The results will be
conveyed to the trial pharmacist so that medication can
be given to participants without anyone else on the team
being aware of the allocation (that is, double-blind).
Blinding
This is a double-blind, randomised, placebo-controlled
feasibility study. Random allocation to treatments will be
undertaken by a statistician who will have no knowledge
of the patient characteristics. The details of the alloca-
tion will be concealed from the research team until all
data collection has been completed. Blinding of partici-
pants and treating physicians to allocation status will be
assured by identical capsule appearance, by identical
labelling between placebo and the active drugs (apart
from labels identifying the patient). Blinding of the cap-
sules, packaging and labelling, will be undertaken byWhen
Screening Randomisation Week 2 Week 4 Week 8 Week 12
x
x




x x x x x x




x x x x
x x
x x x x x





x x x x x
x x x x x
x x x x
nue to have these tests at 2-weekly intervals if there are abnormalities on the
ts are also repeated 4 weeks after finishing the study. Additional blood tests
n, FBC full blood count, GAF Global Assessment of Functioning, HR heart rate,
dical officer, SCID Structured Clinical Interview for DSM-IV.
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and researchers administering the assessment measures
will not be aware of the study drug allocated to the indi-
vidual. In the event a patient develops any side- effects,
where drug unblinding is required, the treating physician
will be made aware of the study drug, possible side-
effects and make the appropriate decision whether to con-
tinue or discontinue the drug. The safety and wellbeing of
the patient will be paramount at all times.
Statistical consideration
Our sample size consideration is based on the hypoth-
esis that there will be a significant difference in changes
from baseline to end-point on the clinical outcome mea-
sures and the cognitive function measures between the
MXT group and the TAU group. With 32 participants
per group, this study will have 80% power to detect a
standardised effect size of 0.53 (medium by the defin-
ition of Cohen) by using a 2-sided significant level of
0.20. As this is a preliminary study, we used a less strin-
gent significance level so as not to miss a promising
effect rather than being too concerned by false positives.
The estimated loss to follow-up rate is 10% and, there-
fore, a total of 72 patients (36 MXT, 36 TAU) are
needed. Our sample size is adequate to estimate the pa-
rameters of acceptability and tolerability to the necessary
degree of precision.
The planned analyses will be by intention-to-treat
(ITT). Careful consideration will be given to the poten-
tial biases arising from the drop-out and missing data.
Group differences in the change of clinical outcome
measures and cognitive function measures at baseline to
12 weeks will be assessed using the t-test or analysis of
covariance (ANCOVA) adjusting for baseline differences.
For repeatedly measured clinical outcomes at baseline, 2,
4, 8 and 12 weeks, we will also use generalised estimating
equations (GEE) to estimate the effect of MXT treatment
on longitudinal outcomes, including baseline values and
time terms as covariates. GEE offers a robust method to




 Signed informed consent, indicating that the subject
understood the purpose of and procedures required
for the study, before the initiation of any study
specific procedures
 Aged 18 to 35 years
 Diagnostic and Statistical Manual-IV (DSM-IV)
diagnosed schizophrenia, schizoaffective disorder,
psychosis not otherwise specified or
schizophreniform disorder
 Early schizophrenia (within first 5 years of diagnosis) Competent and willing to give informed consent
 Medication remained stable 4 weeks prior to
baseline
 Able to take oral medication and likely to complete
the required evaluations
 Female participants of child-bearing capability
must be willing to use adequate contraceptives for
the duration of the study, and willing to have a
pregnancy test pre- treatment and at 10-weekly
intervals while on study medication. Adequate
contraception is defined as use of contraceptive
double barrier system (that is condom and
spermicide) or contraceptive implant, oral
contraceptive or injected depot contraceptive plus
other form of contraceptive, that is a condom.
Females will be considered incapable of
child-bearing if they are 1 year post-menopausal or
irreversibly surgically sterilised
Exclusion criteria
 Violation of any inclusion criteria
 Failure to perform screening or baseline
examinations
 Relevant International Statistical Classification of
Diseases and Related Health Problems (ICD-10)
organic brain disease or neurological diagnoses
(including electrocardiogram (ECG) conduction
abnormalities, neurological disorder, or an active
seizure)
 Patients with liver disease and polyarthritis
 Patients who will meet the criteria for a
DSM-IV-text revision(TR) diagnosis of alcohol or
substance abuse (other than for nicotine) within the
last month or the criteria for DSM-IV-TR alcohol or
substance dependence (other than for nicotine)
within the last 6 months
 Any change of psychotropic medications within the
previous 4 weeks
 Pregnant or lactating women and those of
reproductive age without adequate contraception
 Relevant medical illness will be determined in the
first instance by asking the patient's mental health
care team if the patient has any medical condition/
problems. After consent has been obtained the
research nurse/research doctor will then have access
to the patients’ notes and will assess patient
eligibility to take part in the clinical trial by
scrutinising the patients’ past medical history, most
recent blood results, ECGs, as well as any physical
tests that have been performed on the patient. If
there are any deviations from the ‘norm’ the
investigators will assess the eligibility of the
individual patient. Automatic contraindications will
include significantly impaired renal function,
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pre-existing blood dyscrasias, such as significant
marrow hypoplasia, leukopenia, thrombocytopenia
or anemia.
Interval of assessments
There will be a screening, a randomisation and follow-up
visits. Full clinical assessments (Positive and Negative Syn-
drome Scale (PANSS), Clinical Global Impression (CGI),
Global Assessment of Functioning (GAF), Social Func-
tioning Scale (SFS) and Quality of Life Scale (QLS)) will
be carried out at baseline, 2, 4, 8 and 12 weeks. Social and
cognitive assessments (CogState, IQ using Wechsler Adult
Intelligence Scale (WAIS) block design, Coughlan Learning
Task, Stroop Task, Verbal Fluency) will be carried out at
baseline and 12 weeks. The clinical interview and ratings
will take approximately 50 minutes. The neuropsycholo-
gical assessments will take about 60 to 80 minutes. The
patients will primarily be seen at their treating team’s base.
In special circumstances, if requested by the treating team
or patient, the RAs can visit at home.
RA training and inter-rater reliability
Research assistants in Karachi were trained in Structured
Clinical Interview for DSM-IV (SCID), clinical and neuro-
psychological assessments at the University of Manchester
for a previous SMRI-funded study. Inter-rater reliability
sessions will be conducted by local principle investigators
(PIs) using training videos.
Treatments
Treatment as usual
The patients can be on either first or second generation
antipsychotic medications, as deemed suitable by the re-
sponsible psychiatrist. From our experience with previous
studies there is no major advantage of one generation of
drugs over the other.
Study drug dosage
MXT 7.5 mgs orally once a week) for a 3-month period
as an augmentation agent with TAU. All participants will
also take folic acid 5 mgs/day orally for 6 days a week
(except the day MXT is given), which is routinely given
with MXT to prevent vitamin deficiencies.
Outcome measures for tolerability and acceptability
The definition of tolerability refers to adverse events. An
adverse event is the development of an undesirable medical
condition or the deterioration of a pre-existing medical
condition following or during exposure to a pharmaceut-
ical product, whether or not considered causally related to
the product.
At each clinical assessment (baseline, 2, 4, 8 and
12 weeks and early exit from the study) we will collectspontaneously reported adverse effects and also adminis-
ter an adverse effect check list covering 8 key symptoms/
signs of MXT toxicity (rash, oral ulceration, nausea and
vomiting, diarrhea, new or increasing dyspnea, new or in-
creasing dry cough, severe sore throat, abnormal bruising).
If any of these eight symptoms are present MXT will be
withheld until the case has been discussed with the onsite
investigator. In addition, severe sore throat or abnormal
bruising will lead to an urgent full blood count (FBC) be-
ing conducted, the result of which will be considered by
the investigator in reaching a decision on the patient
continuing in the trial. The routine blood tests at baseline,
2, 4, 6 and 12 weeks will be reviewed by the site investi-
gator within 4 days of being taken and the patient with-
drawn from the study if any indices give cause for concern
(that is are outside pre-specified parameters).
Acceptability is defined as treatment discontinuation
in terms of the number of patients who terminated the
study early (drop-outs) for any reason following randomisa-
tion. We will request an exit interview with all participants
who did not complete the study to explore tolerability and
acceptability.
Clinical outcome measures
1. Negative symptom severity as defined by negative
syndrome subscale score on the PANSS and/or
Negative Symptom Assessment Scale;
2. Full PANSS and positive syndrome subscale score [19]
3. CGI
4. Functional outcome: GAF from DSM-IV (2000) [20]
 SFS self-rating in seven domains [21]
 QLS for treatment effects related to deficit or
negative symptoms [22]Cognitive function measures We will use pencil and
paper tests and CogState; measuring all seven domains
recommended by MATRICS (NIMH initiative). These
domains include speed processing, attention/vigilance,
working memory (nonverbal and verbal), verbal learning,
visual learning, reasoning and problem solving and social
cognitions. We will use the following tests:
1. IQ: using WAIS block design
2. Stroop Task, for divided attention and
processing speed
3. Coughlan Learning Task (Verbal and Visual)
4. Verbal Fluency (words and categories)
Side-effects
Self reported antipsychotic side-effects: Antipsychotic Non-
Neurological Side-Effects Rating Scale (ANNSERS) [23].
Chaudhry et al. Trials 2015, 16:9 Page 6 of 9
http://www.trialsjournal.com/content/16/1/9Safety assessments
Medical history
The primary purpose of screening is to check for inclu-
sion and exclusion criteria. The RAs will arrange for a
doctor to complete checklists for medical history, review
of systems and physical exam. These assessments will be
repeated after 3 months in the trial or at the time of
withdrawal from the study.
Physical assessments
ECG, blood pressure, pulse, height, waist, weight and body
mass index (BMI).
Blood investigations
FBC, erythrocyte sedimentation rate, LFTs, lipid profile,
urea, electrolytes, cytokines and C-reactive protein.
Patients will have FBC and renal and LFTs before
starting treatment and repeated at 2, 4, 6 and 12 weeks.
Remaining investigations will be at baseline and 12 weeks.
Patients will be advised to report all symptoms and signs
suggestive of toxicity and infection, especially sore
throat. Patients will continue to have a 2-weekly FBC
after 6 weeks if there are abnormalities on the 6-week
FBC that do not warrant withdrawal from the study. For
patient safety, full blood monitoring will be repeated at
4 weeks after finishing the study, at week 16.
Additional safety measures
1. At each clinical assessment (baseline, 2, 4, 8 and
12 weeks and early exit from the study) we will
collect spontaneously reported adverse effects and
also administer an adverse effect check list covering
8 key symptoms/signs of MXT toxicity (rash, oral
ulceration, nausea and vomiting, diarrhea, new or
increasing dyspnea, new or increasing dry cough,
severe sore throat, abnormal bruising). If any of
these eight symptoms are present MXT will be
withheld until the case has been discussed with the
onsite investigator. In addition, severe sore throat or
abnormal bruising will lead to an urgent FBC being
conducted the result of which will be considered by
the investigator in reaching a decision on the patient
continuing in the trial.
2. The routine blood tests at baseline, 2, 4, 6 and
12 weeks will be reviewed by the site investigator
within 4 days of being taken and the patient
withdrawn from the study if any indices give cause
for concern (that is are outside pre-specified
parameters).
3. Our administration of a symptoms checklist and
monitoring of FBC, LFTs and renal function is
similar to monitoring advised in the UK
(http://cks.nice.org.uk/dmards#!scenario:8).4. Folic acid, 5 mg once weekly will be given, not on
the same day as MXT, preferably the day after [24].
Folic acid reduces toxic effects of MXT and
improves continuation of therapy and compliance
[25,26]. There is also evidence that increasing folate
levels improves outcomes in schizophrenia [27].
5. Given that participating psychiatrists will have little
or no experience in prescribing MXT, we will
ensure that there is an on-call system such that all
investigators can get immediate expert advice
from a physician in Pakistan who is experienced in
prescribing and monitoring methotrexate.
6. MXT will be dispensed 2-weekly throughout the
study to limit the supply participants have, facilitate
monitoring and adherence. The label will state:
‘Take once a week’.
7. Participants will all have an information leaflet with
safety information.
8. The patients will have access to their RA at all
times, who will be able to contact the research team




Responsible consultant psychiatrists will be approached
and asked if they will allow their patients to take part in
this research study. The research clinician, initially, will
approach the clinical teams to inform them about the
research study, specifically with regard to inclusion and
exclusion criteria. The research clinician will establish a
good working relationship with individual clinical teams.
With regular contact, either by phone or by visits, pa-
tients who are suitable to take part in the research study
will be identified in collaboration with the treating
teams. The consultant psychiatrist will then introduce
the study to the patient if they meet the inclusion cri-
teria, are clinically stable, and the MDT agree the patient
could be a possible participant. With the patient’s con-
sent, the research clinician will visit them and explain
the research study verbally as well as provide them with
the written information. At least 24 hours will be given
to the patient to allow time to read and understand the
patient information sheet. If they are willing to take part,
a meeting will be organised with the patient in order to
obtain consent for the research and also consent for the
research team to have access to their medical notes.
Screening visit
At the screening visit a confirmation of a patient’s suit-
ability for the trial will be carried out. The patient will
be assessed against the inclusion/exclusion criteria, have
a confirmation of their diagnosis, confirmation of con-
sent to take part in the trial and pregnancy testing if
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plete a checklist for medical history, physical examination
and hematological investigations.
Randomisation visit
The baseline clinical and neuropsychological measures
will be completed and the patient will be randomised to
one of the two arms, allocated a unique identification
number and will commence study drug treatment.
The patient will be given a study information card
explaining that they are in a clinical study and are taking
MXT or placebo; the telephone numbers of the senior
research clinicians, the clinical trial office and the name
of the local PIs will be provided.
In accordance with (International Conference for Har-
monisation) Good Clinical Practice ((ICH) GCP) (1996)
[28], copies of all the above will be placed in the patient’s
medical notes along with contact names and telephone
numbers.
Follow-up visits
The first follow-up visit will be after 2 weeks of the
randomisation to complete clinical assessments. There
will be subsequent visits at week 4, 8 and 12. The study
drugs will be dispensed from the local pharmacy depart-
ments. The RAs will collect and deliver these to the
patient at a previously agreed upon location. This will
give the opportunity for the research team to closely
monitor the patient’s physical and mental health, side-
effects and compliance.
Female patients of childbearing capacity taking part in
the clinical trial will have a pregnancy test at baseline, 8
and 12 weeks. If they should become pregnant during
the course of the study, they will be withdrawn from the
study.
During the course of the study the patient’s individual
consultant and mental health care team will be respon-
sible for their overall care. If any concerns do occur with
regard to the research study, the research team will be
contactable to discuss these concerns 24 hours a day,
7 days a week.
Final visit
At this visit all clinical, social, cognitive, physical and
hematological assessments will be completed. Trial medi-
cation will cease.
At all visits the patient’s cumulative clinical drug treat-
ment will be updated from the case notes.
Study coordination
Weekly meetings by local investigators will occur to
coordinate the study. The chief investigator will conduct
2-weekly tele- and video-conference meeting. The accessgrid facility at the University of Manchester will also be
available.
Patient safety
Day-to-day care will remain the responsibility of the
consultant in charge of the patient. However, study
related safety concerns will be the responsibility of
the local PI. The PIs and the co-investigators will be con-
tactable at any time via the clinical trials office or/and
through the senior research clinicians.
Patient withdrawal
Patients may be withdrawn from the treatment study for
the following reasons:
1. At their own request.
2. At the discretion of the investigator.
3. If any patients suffers a serious adverse event, or
moderate to severe adverse drug reaction.
4. Any patients who meet the criteria for insufficient
compliance. This is defined as either taking less than
75% of antipsychotic or trial medication between
assessment points at baseline, 6 weeks and 12 weeks;
or missing trial medications or antipsychotic
medication altogether for 7 days or more at any
period.
5. If a patient becomes pregnant.
Ethical and regulatory standards
Local Research Ethics Committee (LREC) Ethical ap-
proval was obtained from the research and ethics com-
mittee of the Pakistan Institute of Learning and Living
and was submitted to the funding body, Stanley Medical
Research Institute.
Data and Safety Monitoring Board (DSMB) The
DSMB will be constituted according to NIH guidelines,
for oversight and monitoring of the conduct of clinical
trial. DSMB will meet every 6 months to ensure the safety
of participants and the validity and integrity of the data.
Declaration of Helsinki The research study will be
performed in accordance with the guidelines in the
Declaration of Helsinki (1974) as revised in Tokyo (1975),
Venice (1983), Hong Kong (1989), South Africa (1996)
and Scotland (2000).
All members of the research team will comply with
ICH/GCP Guidelines (1996), which are consistent with
principles that have their origin in the Declaration of
Helsinki.
Team expertise Five of the investigators have extensive
experience in treatment and management of schizoph-
renia (Chaudhry, Haddad, Husain, Kazmi, Rahman and
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be important components of success in recruitment. All
investigators have been closely involved in setting up the
methodology and software for gathering clinical and
research data in patients with psychosis. Chaudhry and
Husain will oversee the training of RAs in recruiting
patients and in diagnostic and symptom ratings. All of
the investigators were involved in feasibility study for
this trial. Deakin, Haddad and Chaudhry are experts in
psychopharmacology. Chaudhry and Husain have been PIs
in a number of multicentre trials funded by the Medical
Research Council (MRC) and SMRI in schizophrenia and
have much experience of large-scale treatment studies in
psychosis. Chaudhry and Husain have published longitu-
dinal studies on negative symptoms, cognition and quality
of life. Husain, Chaudhry, Kazmi, Rahman and colleagues
ran the SMRI trial of minocycline.
Discussion
Evidence suggests inflammatory processes are involved
in the pathogenesis of schizophrenia and anti-inflammatory
treatments have shown to have some beneficial effects.
MXT is a known immuno-suppressant and anti-
inflammatory drug. The aim of the this study is to
evaluate the effectiveness of MXT added to TAU on
positive and negative symptoms, cognitive and social
functioning and quality of life of patients suffering from
schizophrenia.
Trial status
This clinical trial was registered in February of 2014.
The study is currently recruiting participants. The esti-
mated study completion date is December 2015. Please
refer to this study by its ClinicalTrials.gov identifier:
NCT02074319.
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MXT: methotrexate; NMDA: N-methyl-D-aspartate; NO: nitric oxide;
PANSS: Positive and Negative Syndrome Scale; PET: positron emission
tomography; PI: principal investigator; QLS: Quality of Life Scale; QOL: quality
of life; RA: research assistants; RMO: resident medical officer; ROS: reactive
oxygen species; SFS: Social Functioning Scale; SCID: Structured Clinical
Interview for DSM-IV; sIL-2R: soluble IL-2 receptor; SMRI: Stanley Medical
Research Institute; TAU: treatment as usual; TNF-alpha: tumour necrosis
factor-alpha; TRS: Treatment Resistant Schizophrenia; UK: United Kingdom;
WAIS: Wechsler Adult Intelligence Scale.Competing interests
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